Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

CONCLUSION: Platinum agents do not improve outcomes in patients with basal subtype TNBC RD post-NAC and are associated with more severe toxicity when compared with capecitabine. Participants had a lower than expected 3-year iDFS regardless of study treatment, highlighting the need for better therapies in this high-risk population.PMID:34092112 | DOI:10.1200/JCO.21.00976

Source: Clinical Genitourinary Cancer - June 7, 2021 Category: Cancer & Oncology Authors: Ingrid A Mayer Fengmin Zhao Carlos L Arteaga William F Symmans Ben H Park Brian L Burnette Amye J Tevaarwerk Sofia F Garcia Karen L Smith Della F Makower Margaret Block Kimberly A Morley Chirag R Jani Craig Mescher Shabana J Dewani Bernard Tawfik Lisa E F Source Type: research